Better antibiotic combinations for drug-resistant Acinetobacter and Klebsiella
Project 2 Hollow Fiber Project
Finding better antibiotic combinations and dosing plans for people with drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11164512 on NIH RePORTER |
What this research studies
Researchers will use laboratory infection models (including hollow-fiber systems) to test different antibiotic combinations and dosing schedules against carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. They will measure how the bacteria respond at the genetic, transcriptomic, and protein levels and map which drug targets are hit inside intact bacteria. Those mechanistic data will be used to design combination regimens that maximize bacterial killing and reduce the chance resistance emerges. The goal is to produce dosing guidance and candidate combinations that can inform future clinical testing.
Who could benefit from this research
Good fit: People with infections caused by carbapenem-resistant Acinetobacter baumannii or carbapenem-resistant Klebsiella pneumoniae, especially hospital-acquired or difficult-to-treat infections, would be most relevant to this work.
Not a fit: Patients without multidrug-resistant Acinetobacter or Klebsiella infections, or those who need immediate lifesaving treatment, are unlikely to benefit directly from this preclinical research.
Why it matters
Potential benefit: If successful, this work could lead to combination antibiotic regimens and dosing strategies that more reliably cure infections caused by carbapenem-resistant Acinetobacter and Klebsiella and slow resistance development.
How similar studies have performed: Previous hollow-fiber and laboratory pharmacodynamic work has helped shape dosing recommendations and select combinations, but translating these findings into consistently improved clinical outcomes for CRAB and CRKP remains difficult.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Drusano, George Louis — University of Florida
- Study coordinator: Drusano, George Louis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.